Strakan International Ltd.

To evaluate the efficacy and safety of granisetron transdermal patch in preventing nausea and vomiting caused by moderate to severe emetogenic anti-cancer chemotherapy, and to provide scientific and reliable clinical data for its drug registration in China.

Primary objective: To compare the pharmacokinetic characteristics of a single 52 cm2 granisetron transdermal patch applied on the outer side of the upper arm for 6 consecutive days with oral administration of 1 mg granisetron tablets twice daily for 5 consecutive days in healthy Chinese subjects. Secondary objective: To evaluate the local tolerability and safety of the granisetron transdermal patch.